<DOC>
	<DOCNO>NCT00003612</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness combine paclitaxel , carboplatin , trastuzumab treat woman metastatic breast cancer overexpresses HER2 .</brief_summary>
	<brief_title>Combination Chemotherapy Trastuzumab Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate associate two different treatment schedule paclitaxel , carboplatin , trastuzumab ( Herceptin ) woman overexpressed HER-2 growth factor receptor metastatic breast cancer . ( Schedule A close accrual effective 05/16/2003 ) . - Compare time progression median survival patient treat schedule . - Compare toxicity treatment schedule patient . OUTLINE : This multicenter study . Patients stratify accord prior adjuvant therapy ( none v le 6 month v least 6 month ) , estrogen receptor ( ER ) status progesterone receptor ( PR ) status initial diagnosis ( ER positive/PR positive unknown v ER positive/PR negative v ER positive unknown/PR negative ) , menopausal status ( pre v post ) , performance status ( 0 1 v 2 ) . Patients assign 1 2 treatment schedule . - Schedule A : Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute trastuzumab ( Herceptin ) IV 90 minute day 1 week 1 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Patients receive trastuzumab IV 30 minute every 3 week disease progression . ( Schedule A close accrual effective 05/16/2003 ) . - Schedule B : Patients receive paclitaxel IV 1 hour follow carboplatin IV 15 minute day 1 week 1-3 trastuzumab IV 90 minute immediately carboplatin day 1 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients receive trastuzumab IV 30 minute every 3 week disease progression . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 36-92 patient ( 18-46 per treatment schedule ) accrue study within 7-18.5 month . ( Schedule A close accrual effective 05/16/2003 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma breast Strong overexpression HER2 immunohistochemistry ( 3+ ) 02+ tumor allow demonstrate amplification FISH Bidimensionally measurable disease Brain metastasis must represent sole site disease No untreated brain metastasis receive radiotherapy Previously treat brain metastasis continue response radiotherapy and/or surgery least 2 month allow Hormone receptor status : Positive negative PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No myocardial infarction within past 6 month No congestive heart failure unstable angina No clinically significant pericardial effusion arrhythmia Other : No invasive malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No active uncontrolled infection No prior allergic reaction Cremophor EL , anesthetic , muscle relaxant Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : Prior adjuvant chemotherapy allow Prior taxane therapy allow No prior cisplatin carboplatin No prior chemotherapy metastatic disease Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy 25 % marrow At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery recover Other : At least 7 day since prior parenteral antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>